Quinine HClAntimalarial CAS# 130-89-2 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 130-89-2 | SDF | Download SDF |
PubChem ID | 91558 | Appearance | Powder |
Formula | C20H25ClN2O2 | M.Wt | 360.88 |
Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in water and to 100 mM in DMSO | ||
Chemical Name | (R)-[(2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;hydrochloride | ||
SMILES | COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O.Cl | ||
Standard InChIKey | LBSFSRMTJJPTCW-DSXUQNDKSA-N | ||
Standard InChI | InChI=1S/C20H24N2O2.ClH/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18;/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3;1H/t13-,14-,19-,20+;/m0./s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. Quinine HCl produces alpha-adrenergic blockade. 2. Quinine modifies catecholamine- and calcium-induced myocardial contractile force responses. |
Targets | Adrenergic Receptor |
Quinine HCl Dilution Calculator
Quinine HCl Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.771 mL | 13.855 mL | 27.71 mL | 55.4201 mL | 69.2751 mL |
5 mM | 0.5542 mL | 2.771 mL | 5.542 mL | 11.084 mL | 13.855 mL |
10 mM | 0.2771 mL | 1.3855 mL | 2.771 mL | 5.542 mL | 6.9275 mL |
50 mM | 0.0554 mL | 0.2771 mL | 0.5542 mL | 1.1084 mL | 1.3855 mL |
100 mM | 0.0277 mL | 0.1386 mL | 0.2771 mL | 0.5542 mL | 0.6928 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Protopine
Catalog No.:BCN6165
CAS No.:130-86-9
- Thioridazine HCl
Catalog No.:BCC3869
CAS No.:130-61-0
- 1,4-Naphthoquinone
Catalog No.:BCN8420
CAS No.:130-15-4
- Senecionine
Catalog No.:BCN2129
CAS No.:130-01-8
- Iloperidone hydrochloride
Catalog No.:BCC4212
CAS No.:1299470-39-5
- Dapoxetine HCl
Catalog No.:BCC5064
CAS No.:129938-20-1
- Amicarbazone
Catalog No.:BCC5464
CAS No.:129909-90-6
- MC 976
Catalog No.:BCC1734
CAS No.:129831-99-8
- ODM-201
Catalog No.:BCC3796
CAS No.:1297538-32-9
- Anemoside B4
Catalog No.:BCN1276
CAS No.:129741-57-7
- Anemoside A3
Catalog No.:BCN2328
CAS No.:129724-84-1
- 3-Hydroxylanost-9(11)-24-dien-26-oic acid
Catalog No.:BCN1586
CAS No.:129724-83-0
- Quinine
Catalog No.:BCN2341
CAS No.:130-95-0
- I-BET151 (GSK1210151A)
Catalog No.:BCC4476
CAS No.:1300031-49-5
- GSK1324726A
Catalog No.:BCC4038
CAS No.:1300031-52-0
- Dehydrocorydaline nitrate
Catalog No.:BCN2745
CAS No.:13005-09-9
- Mafenide Acetate
Catalog No.:BCC5236
CAS No.:13009-99-9
- Lomustine
Catalog No.:BCC4794
CAS No.:13010-47-4
- (+)-Igmesine hydrochloride
Catalog No.:BCC5902
CAS No.:130152-35-1
- Ergosterol glucoside
Catalog No.:BCN7327
CAS No.:130155-33-8
- Torilolone
Catalog No.:BCN6659
CAS No.:13018-09-2
- Torilin
Catalog No.:BCN6611
CAS No.:13018-10-5
- Cirsimarin
Catalog No.:BCN6821
CAS No.:13020-19-4
- N-(4-Hydroxyphenylacetyl)spermine
Catalog No.:BCC6594
CAS No.:130210-32-1
The perception of quinine taste intensity is associated with common genetic variants in a bitter receptor cluster on chromosome 12.[Pubmed:20675712]
Hum Mol Genet. 2010 Nov 1;19(21):4278-85.
The perceived taste intensities of Quinine HCl, caffeine, sucrose octaacetate (SOA) and propylthiouracil (PROP) solutions were examined in 1457 twins and their siblings. Previous heritability modeling of these bitter stimuli indicated a common genetic factor for quinine, caffeine and SOA (22-28%), as well as separate specific genetic factors for PROP (72%) and quinine (15%). To identify the genes involved, we performed a genome-wide association study with the same sample as the modeling analysis, genotyped for approximately 610,000 single-nucleotide polymorphisms (SNPs). For caffeine and SOA, no SNP association reached a genome-wide statistical criterion. For PROP, the peak association was within TAS2R38 (rs713598, A49P, P = 1.6 x 10(-104)), which accounted for 45.9% of the trait variance. For quinine, the peak association was centered in a region that contains bitter receptor as well as salivary protein genes and explained 5.8% of the trait variance (TAS2R19, rs10772420, R299C, P = 1.8 x 10(-15)). We confirmed this association in a replication sample of twins of similar ancestry (P = 0.00001). The specific genetic factor for the perceived intensity of PROP was identified as the gene previously implicated in this trait (TAS2R38). For quinine, one or more bitter receptor or salivary proline-rich protein genes on chromosome 12 have alleles which affect its perception but tight linkage among very similar genes precludes the identification of a single causal genetic variant.
Quinine-HCl-induced modification of receptor potentials for taste stimuli in frog taste cells.[Pubmed:7795491]
Zoolog Sci. 1995 Feb;12(1):45-52.
After frog taste cells were adapted to 1 mM quinine-HCl (Q-HCl) for 10 sec, modification of receptor potentials in the taste cells induced by salt, acid, sugar and bitter stimuli was studied with microelectrodes. The phasic component of receptor potentials induced by 0.1 M NaCl, KCl, NH4Cl and MgCl2 was enhanced following adaptation to Q-HCl. The rate of rise of receptor potentials in response to the salts was increased after Q-HCl adaptation. The amplitude and the rate of rise of receptor potentials induced by 1 mM acetic acid were larger after Q-HCl adaptation than after water adaptation. The amplitude of phasic component and rate of rise of receptor potentials for 0.5 M sucrose after Q-HCl were the same as those after water. The amplitudes of tonic receptor potentials for 1 mM Q-H2SO4, brucine and picric acid after Q-HCl adaptation were the same as those after 1 mM NaCl adaptation. Correlation coefficient between taste cell responses induced by 1 mM Q-HCl and 1 mM Q-H2SO4 was very high, but those between 1 mM Q-HCl and 1 mM brucine responses and between 1 mM Q-HCl and 1 mM picric acid responses were low. This indicates that Q-HCl and Q-H2SO4 bind to the same receptor site, but brucine and picric acid bind to different receptor sites to which Q-HCl does not bind.
alpha-Adrenergic blocking properties of quinine HCl.[Pubmed:6103815]
Eur J Pharmacol. 1980 May 2;63(2-3):159-66.
In the anesthetized dog, Quinine HCl (50 mg/kg, i.v.) infused over a 20 min period produced 1 22% maximum decrease in diastolic blood pressure, a 53% increase in pulse pressure and a 52% increase in myocardial contractile force. The initial positive inotropic response was maximal in the first 5--15 min of the quinine infusion and decreased to near control levels 40 min following the quinine infusion. Quinine caused a marked reduction in the noradrenaline (NA) pressor response, blockade of the adrenaline (A) pressor response, partial blunting of the angiotensin II (AII) pressor effect but no change in the depressor effect of isoprenaline (I). The positive inotropic effects of CaCl2 were reduced and the duration of contractile action to both I and CaCl2 was significantly prolonged by quinine. In isolated rabbit thoracic aortic strips, quinine produced a parallel, dose-related shift of the concentration-response curve for NA to the right but did not affect the maximum responses. A pA2 of 4.91 was estimated by the method of Schild. The determined line had a slope of -0.84 which is similar to a theoretical slope of -1.0 and indicates a direct relationship between the number of receptors occupied and the contractile response. The responses to AII and histamine (H) were not altered by quinine. These results suggest that Quinine HCl produces alpha-adrenergic blockade; additionally, quinine modifies catecholamine- and calcium-induced myocardial contractile force responses.